Conatus Pharmaceuticals Inc. (CNAT) News

Conatus Pharmaceuticals Inc. (CNAT): $0.56

0.00 (0.18%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add CNAT to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked


in industry

Filter CNAT News Items

CNAT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CNAT News From Around the Web

Below are the latest news stories about Conatus Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNAT as an investment opportunity.

Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

Yahoo | December 2, 2019

NASH Scorecard Year to Date: The Winners and the Losers

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Yahoo | November 29, 2019

Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

SAN DIEGO, Nov. 18, 2019 -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional.

Yahoo | November 18, 2019

Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 6, 2019

Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results

SAN DIEGO, Nov. 05, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent.

Yahoo | November 5, 2019

Is Conatus Pharmaceuticals Inc.'s (NASDAQ:CNAT) CEO Paid Enough Relative To Peers?

In 2005 Steven Mento was appointed CEO of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). First, this article will compare…

ACI Information Group | November 3, 2019

Caspase 3 Market Comprehensive Study by Leading Players- Aptose Biosciences, BeyondSpring Pharmaceuticals, Conatus Pharmaceuticals

Nov 02, 2019 (HTF Market Intelligence via COMTEX) -- An extensive analysis of the Global Caspase 3 market strategy of the leading companies in the precision…

MarketWatch | November 2, 2019

Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | August 6, 2019

The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase defici...

Benzinga | August 3, 2019

Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should Know

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research | July 31, 2019


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!